F. Kanzawa
Pharmacology Division
National Cancer Center Research Institute
Chuo-ku
Tokyo
Japan
Name/email consistency: high
- In vitro interactions of a new derivative of spicamycin, KRN5500, and other anticancer drugs using a three-dimensional model. Kanzawa, F., Nishio, K., Fukuoka, K., Sunami, T., Saijo, N. Cancer Chemother. Pharmacol. (1999)
- Evaluation of synergism by a novel three-dimensional model for the combined action of cisplatin and etoposide on the growth of a human small-cell lung-cancer cell line, SBC-3. Kanzawa, F., Nishio, K., Fukuoka, K., Fukuda, M., Kunimoto, T., Saijo, N. Int. J. Cancer (1997)
- Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines. Kanzawa, F., Nishio, K., Ishida, T., Fukuda, M., Kurokawa, H., Fukumoto, H., Nomoto, Y., Fukuoka, K., Bojanowski, K., Saijo, N. Br. J. Cancer (1997)